This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis

This study has been completed.
Information provided by (Responsible Party):
Celgene Identifier:
First received: November 26, 2013
Last updated: February 14, 2017
Last verified: February 2017
To determine the optimal route of administration, dose level, and safety of intravenous and subcutaneous dosing of sotatercept for maintaining hemoglobin levels in subjects who are on hemodialysis.

Condition Intervention Phase
Anemia Kidney Failure, Chronic Biological: Sotatercept Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Multicenter, Randomized, Open-Label , Multiple-Dose Study of Intravenous and Subcutaneous Administration of Sotatercept (ACE-011) in Subjects With End-Stage Kidney Disease on Hemodialysis Switched From Erythropoeisis Stimulating Agents With Staggered Dose Group Escalation in Part 1 Followed by a Parallel Group, Active Controlled Study of Selected Dose(s) and Regimen(s) in Part 2: To Evaluate the Pharmacokinetics, Safety, Tolerability, Efficacy, Dosing Regimen, and Pharmacodynamics of Sotatercept

Resource links provided by NLM:

Further study details as provided by Celgene:

Primary Outcome Measures:
  • Pharmacokinetics (Cmax) [ Time Frame: 28 days ]
    Maximum observed concentration in serum

  • Pharmacokinetics (Tmax) [ Time Frame: 28 days ]
    Time to maximum concentration

  • Pharmacokinetics (AUC 28d) [ Time Frame: 28 days ]
    Area under the concentration-time curve

  • Pharmacokinetics (t1/2,z) [ Time Frame: 211 days ]
    Terminal half life

  • Adverse Event [ Time Frame: 211 days ]
    treatment emergent adverse sevents (TEAEs) and number of subjects with TEAEs.

Secondary Outcome Measures:
  • Efficacy [ Time Frame: 113 days ]
    Change in mean hemoglobin concentration between baseline and day 113

  • Bone Turnover [ Time Frame: 211 days ]
    Change in serum bone biomarker concentrations between baseline and end of study (day 211)

Enrollment: 49
Study Start Date: November 2013
Study Completion Date: August 2016
Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intravenous Dose Group 1, 2, and 3
Intravenous Dose Group 1 starting at 0.1 mg/kg and escalated in Dose Groups 2 (0.2 mg/kg) and Dose Group 3 (0.1, 0.2, 0.3, 0.4 mg/kg, titrated based on titration rules, administered every 14 days)
Biological: Sotatercept
Sotatercept is dosed intravenously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.
Other Name: ACE-011
Experimental: Subcutaneous Dose Group 1, 2, and 3
Subcutaneous Dose Group 1 starting at 0.13 mg/kg and escalated in Dose Groups 2 (0.26 mg/kg) and Dose Group 3 (0.4 to 0.5 mg/kg, titrated based on titration rules, administered every14 days)
Biological: Sotatercept
Sotatercept is dosed subcutaneously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.
Other Name: ACE-011


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Males or females ≥ 18 years of age.
  2. Subjects on at least 6 hours of hemodialysis per week, for at least 12 weeks before screening
  3. Subjects must be on a stable intravenous or subcutaneous dose of Erythropoietin Stimulating Agents (excluding methoxy polyethylene glycol-epoetin beta [Mircera]) to maintain hemoglobin.
  4. A mean predialysis hemoglobin concentration ≥ 10 g/dL (grams per deciliter) to ≤ 12 g/dL (≥ 100 g/L (grams per liter) to ≤ 120 g/L) obtained from three consecutive days.

4. A Body Mass Index value ≥ 18.5 kg/m2 (kilograms per m2) at screening. 5. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted.

6. Able to adhere to the study visit schedule and comply with all protocol requirements.

Exclusion Criteria:

  1. Non renal causes of anemia
  2. Subjects on peritoneal dialysis.
  3. Systemic hematological disease
  4. Uncontrolled diabetes mellitus (HbA1c (hemoglobin A1c) > 9%) at screening.
  5. Uncontrolled hypertension defined as mean of home systolic blood pressure > 160 mm Hg (millimeter of mercury) or mean of home diastolic blood pressure > 90 mm Hg calculated once during the screening period prior to randomization
  6. Subjects with heart failure
  7. History of malignancy (except excised and cured non-melanoma skin cancer, or cervical carcinoma in situ that was surgically ablated more than 5 years ago).
  8. Anticipated or scheduled living donor renal transplant during the course of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01999582

Centre Hospitalier EpiCURA - Clinique Louis Caty de Baudour
Baudour, Belgium, 7331
Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg
Leuven, Belgium, 3000
Liege, Belgium, 4000
KfH Nierenzentrum Coburg
Coburg, Germany, 96450
Gemeinschaftspraxis und Dialysezentrum Karlstrass
Düsseldorf, Germany, 40210
KfH Kuratorium für Dialyse und Nierentransplantation e.v.
München, Germany, 80337
KfH Nierenzentrum Rosenheim
Rosenheim, Germany, 83022
Nephrocare Faro
Faro, Portugal, 8000
Hospital de Santa Maria
Lisboa, Portugal, 1649-035
Nephrocare Portimao
Portimão, Portugal, 8500-311
Complejo Hospitalario de Torrecardenas
Almeria, Spain, 04009
Hospital Universitari Vall d'Hebron
Barcelona, Spain, 08035
Hospital Clinic of Barcelona
Barcelona, Spain, 08036
Hospital Universitario Reina Sofia
Córdoba, Spain, 14004
Hospital Galdakao-Usansolo
Galdakao, Spain, 48960
Servicio de Nefrologia Hospital General Universitario Gregorio Maranon
Madrid, Spain, 28007
Hospital 12 de Octubre
Madrid, Spain, 28041
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, Madrid, Spain, 28222
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, Spain, 39008
Hospital de Torrevieja
Torrevieja (Alicante), Spain, 03186
United Kingdom
Cambridge University Hospitals NHS Trust
Cambridge, United Kingdom, CB2 0QQ
Glasgow Royal Infirmary
Glasgow, United Kingdom, G11 6NT
St Georges Healthcare NHS Trust
London, United Kingdom, SW17 0QT
Sponsors and Collaborators
Study Director: William Smith, MD Celgene Corporation
  More Information

Responsible Party: Celgene Identifier: NCT01999582     History of Changes
Other Study ID Numbers: ACE-011-REN-002
2012-003788-23 ( EudraCT Number )
Study First Received: November 26, 2013
Last Updated: February 14, 2017

Keywords provided by Celgene:
End Stage Kidney Disease
Chronic Kidney Disease
Erythrpoietin Stimulating Agent (ESA)

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency
Kidney Failure, Chronic
Renal Insufficiency, Chronic
Urologic Diseases processed this record on September 19, 2017